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Inclusions of Tar DNA- binding protein 43 (TDP-43) are a pathological hallmark of amyotrophic lateral
sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43-positive inclusions (FTLD-TDP). Pa-
thological TDP-43 exhibits the disease-speciﬁc biochemical signatures, which include its ubiquitination,
phosphorylation and truncation. Recently, we demonstrated that the extreme N-terminus of TDP-43
regulates formation of abnormal cytoplasmic TDP-43 aggregation in cultured cells and primary neurons.
However, it remained unclear whether this N-terminal domain mediates TDP-43 aggregation and the
associated toxicity in vivo. To investigate this, we expressed a GFP-tagged TDP-43 with a nuclear loca-
lization signal mutation (GFP-TDP-43NLSm) and a truncated form without the extreme N-terminus
(GFP-TDP-4310-414-NLSm) by adeno-associated viral (AAV) vectors in mouse primary cortical neurons and
murine central nervous system. Compared to neurons containing GFP alone, expression of
GFP-TDP-43NLSm resulted in the formation of ubiquitin-positive cytoplasmic inclusions and activation of
caspase-3, an indicator of cell death. Moreover, mice expressing GFP-TDP-43NLSm proteins show reactive
gliosis and develop neurological abnormalities. However, by deletion of TDP-43's extreme N-terminus,
these pathological alterations can be abrogated. Together, our study provides further evidence con-
ﬁrming the critical role of the extreme N-terminus of TDP-43 in regulating protein structure as well as
mediating toxicity associated with its aggregation.
This article is part of a Special Issue entitled SI:RNA Metabolism in Disease.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
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Amyotrophic lateral sclerosis (ALS) is a devastating neurode-
generative disease that affects upper and lower motor neurons in
the brain and spinal cord. Degeneration of neurons in these affected
areas causes muscle weakness and atrophy throughout the body
and often leads to death from respiratory failure usually within 3–5
years of onset (Robberecht and Philips, 2013). Frontotemporal de-
mentia (FTD) is a clinical syndrome, caused by the atrophy of frontal
and temporal lobes, associated with progressive changes in beha-
vior, personality, language, and/or motor function (Dormont and
Seidenwurm, 2008). FTD accounts for 5–15% of all cases of de-
mentia, and is the second most common form of early-onset de-
mentia after Alzheimer's disease (Rademakers et al., 2012). Fron-
totemporal lobar degeneration with TDP-43-positive inclusions
(FTLD-TDP) is the most common pathological subgroup of FTD (Arai
et al., 2006; Neumann et al., 2006); the characteristic formation of
ubiquitin-positive inclusions in affected neurons led to its previous
description as FTLD-U. ALS and FTLD-TDP are referred to as TDP-43
proteinopathies due to the hallmark presence of TDP-43 cyto-
plasmic inclusions (Chen-Plotkin et al., 2010; Janssens and Van
Broeckhoven, 2013). Other common pathological features include
TDP-43 phosphorylation and ubiquitination as well as cleaved
fragments of TDP-43 (Arai et al., 2006; Neumann et al., 2006). Un-
like in disease, TDP-43 normally localizes to cell nuclei under a
physiological steady state and is reported to play roles in regulating
transcription, splicing of pre-mRNA, translation, stabilizing mRNA,
and processing of microRNAs (Ayala et al., 2011; Baralle et al., 2013;
Chen-Plotkin et al., 2010; Fiesel et al., 2010, 2012; Strong, 2010;
Volkening et al., 2009). TDP-43, a heterogeneous nuclear ribonu-
cleoprotein (hnRNP), contains an N-terminal domain consisting of a
nuclear localization signal (NLS) and a nuclear export signal (NES),
two RNA-binding domains (RBDs) and a C-terminal glycine-rich
domain. Of interest, TDP-43 monomers bind to each other to form
homodimers in vitro (Kuo et al., 2009; Shiina et al., 2010; Zhang
et al., 2009). Recently, we and others have reported that the
N-terminus of TDP-43 is the crucial element in regulating its self-
interaction (Chang et al., 2012; Wang et al., 2013; Zhang et al., 2013).
Moreover, we demonstrated that TDP-43 homodimerization also
plays an important role in modulating the normal biological activity
of TDP-43 (Zhang et al., 2013).
TDP-43 pathology is found in the majority of sporadic and fa-
milial ALS, and the most common subtype of FTD, FTLD-TDP. Mu-
tations in Tardbp, the gene encoding TDP-43, are associated with
familial as well as some cases of sporadic ALS. Considering these
factors, TDP-43 is believed to be one of the most important factors
in ALS and FTLD-TDP pathogenesis (Cohen et al., 2011). Similar to
the roles of the aggregated proteins found in other neurodegen-
erative diseases such as Alzheimer's disease (AD), Parkinson's dis-
ease (PD), and polyglutamine diseases (Forman et al., 2004; Taylor
et al., 2002), these cytoplasmic TDP-43 inclusions may contribute to
disease pathogenesis through a toxic gain of function mechanism
(Lee et al., 2012). Indeed, previous studies have shown that the
expression of full length TDP-43 with mutations in the NLS se-
quence (TDP-43NLSm) in mouse or rat brain resulted in formation of
cytoplasmic TDP-43 aggregates and neurodegeneration, as well asdisease-relevant motor deﬁcits (Dayton et al., 2013; Igaz et al., 2011;
Walker et al., 2015). Of importance, suppression of TDP-43NLSm
expression rescues above pathological phenotypes, indicating that
clearance of cytoplasmic TDP-43 accumulation and aggregation
provides protection (Igaz et al., 2011; Walker et al., 2015).
Recently, we demonstrated that the extreme N-terminus of TDP-43
is required for the cytoplasmic aggregation of TDP-43NLSm and the
associated toxicity in primary cultured neurons (Zhang et al., 2013).
Consistent with our ﬁnding, Budini et al. further discovered that the
N-terminal region of TDP-43 is required for sequestration of full length
TDP-43 into cytoplasmic TDP-43 inclusions and subsequent TDP-43
loss-of-function in cultured cells (Budini et al., 2015). Considering the
important roles of the N-terminal region of TDP-43 in regulation of
TDP-43 aggregation, we sought to further determine whether this
N-terminal domain regulates TDP-43 aggregation and the associated
toxicity in vivo. In the present study, we used adeno-associated viral
vectors (AAV) to express TDP-43NLSm or TDP-4310-414-NLSm in the
murine central nervous system. We found that the deletion of the ﬁrst
10 amino acids signiﬁcantly mitigates TDP-43 aggregation and rescues
neurodegeneration in vivo. This data conﬁrm the critical role of the
extreme N-terminus of TDP-43 in regulating protein structure and
aggregation. Therefore, the identiﬁcation of agents targeting this re-
gion might be a promising therapeutic strategy to treat TDP-43
proteinopathies.2. Results
2.1. Deletion of the TDP-43 N-terminus attenuates aggregate for-
mation and the associated toxicity in mouse primary neurons
We previously showed that the overexpression of TDP-43NLSm,
but not TDP-4310-414-NLSm, resulted in the formation of TDP-43 ag-
gregates in the cytoplasm and impairment of neuronal outgrowth
in mouse primary neuronal cultures (Zhang et al., 2013). To further
investigate the link between N-terminus of TDP-43 and neuro-
toxicity in vitro, we transduced mouse cortical primary cultures
with recombinant AAV2/1 containing GFP, GFP-TDP-43NLSm or
GFP-TDP-4310-414-NLSm for 5 days. Consistent with our previous re-
port (Zhang et al., 2013), confocal analysis revealed that expression
of GFP-TDP-43NLSm results in formation of cytoplasmic aggregates
(Fig. 1A). In contrast, expression of GFP-TDP-4310-414-NLSm and GFP
alone in primary neurons showed diffuse distribution (Fig. 1A).
Compared to GFP alone, Western blot analysis revealed that ex-
pression of GFP-TDP-43NLSm and GFP-TDP-4310-414-NLSm respectively
leads to a 3.2 and 1.6-fold increase in levels of active caspase-3
(Fig. 1B and C). Of note, while the levels of TDP-43 protein were
comparable between GFP-TDP-43NLSm and GFP-TDP-4310-414-NLSm
(Fig. 1B and C), expression of GFP-TDP-43NLSm induced much greater
activation of caspase-3 than GFP-TDP-4310-414-NLSm (Fig. 1B and C).
2.2. Intracerebroventricular (ICV) injection of AAV2/9-TDP-43 results
in expression of TDP-43 proteins throughout mouse brain
Since AAV2/9 capsid serotype has been shown to mediate a
more widespread distribution of a target gene than AAV2/1 in
Fig. 1. Deletion of the TDP-43 N-terminus attenuates aggregate formation and the associated toxicity in mouse primary neurons. (A) Expression of GFP-TDP-43NLSm resulted
in formation of cytoplasmic aggregates, whereas GFP-TDP-43NLSm-10-414 and GFP alone showed diffuse distribution throughout mouse primary neurons. Scale bar represents
10 mm. Western blot (B) and densitometric analysis of blots (C) revealed that, compared to GFP, expression of GFP-TDP-43NLSm signiﬁcantly induces the levels of activated
caspase-3. In contrast, deletion of the ﬁrst 10 residues dramatically abrogates caspase-3 activation. Of note, expression levels of TDP-43 protein were comparable between
GFP-TDP-43NLSm and GFP-TDP-43NLSm-10-414 (B, C). Data represents mean7SEM of three separate experiments. *Po0.05, **Po0.01, n.s. not signiﬁcant, as analyzed by one-
way ANOVA with Tukey's post-hoc analysis.
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taining either GFP, GFP-TDP-43NLSm or GFP-TDP-4310-414-NLSm into
cerebroventricles of P0 neonatal mice at low dose (1.251010
particles) or high dose (5.01010 particles) to further evaluate the
neurotoxicity of cytoplasmic TDP-43 aggregates in vivo. Twenty-
eight days following ICV delivery, the mice were harvested to
measure the expression of GFP-TDP-43 in the brain. We observed
that although the protein levels of GFP-TDP-43NLSm were higher
than that of GFP-TDP-4310-414-NLSm when the low dose of virus was
used (Fig. 2A and B), a high dose of GFP-TDP-4310-414-NLSm pro-
duced comparable protein levels as that of GFP-TDP-43NLSm
(Fig. 2A and B). In contrast to protein expression, the mRNA levels
of GFP-TDP-4310-414-NLSm assessed with primer sets targeting ei-
ther GFP (Fig. 2C) or human TDP-43 (Fig. 2C) at both low and high
doses were signiﬁcantly higher than that of GFP-TDP-43NLSm at a
low dose, suggesting the TDP-43NLSm protein may be more stable
than TDP-4310-414-NLSm. To verify that the expression of
GFP-TDP-43NLSm or GFP-TDP-4310-414-NLSm did not reduce the
protein and mRNA levels of endogenous mouse TDP-43 (Fig. 2A, B,
D), the levels of mSort1_17b (mouse sortilin 1 including exon 17b),
a splicing variant of mSort1 that is signiﬁcantly increased during
downregulation of mouse TDP-43, were measured (Prudencioet al., 2012; Xu et al., 2013). A decrease in mSort1 RNA was not
detected in the brains of GFP-TDP-43NLSm mice (Fig. 2D), further
conﬁrming a lack of reduction of mouse TDP-43 and its activity.
2.3. Deletion of the TDP-43 N-terminus attenuates cell death, re-
active gliosis, and motor deﬁcits associated with TDP-43 aggregates
Considering TDP-43 protein levels were comparable in mice in-
jected with low-doses of GFP-TDP-43NLSm and high-doses of
GFP-TDP-4310-414-NLSm, we sought to evaluate the resulting behavioral
abnormalities of these mice. Twenty-eight days after ICV injection, all
the GFP-TDP-43NLSm-expressing mice exhibited a hind limb clasping
phenotype when suspended by the tail (Fig. 3A, Supplementary Video
1). In contrast, GFP or GFP-TDP-4310-414-NLSm-injected mice showed a
normal escape response by splaying their hind limbs (Fig. 3A, Sup-
plementary Video 2, 3). Pathological analysis of the brains with GFP
antibody revealed that TDP-43-positive aggregates were observed in a
subset of neurons expressing GFP-TDP-43NLSm in cortical regions (ar-
row, Fig. 3B). Of note, these TDP-43 aggregates were also ubiquitin-
positive (Fig. 3C). In contrast, TDP-43 aggregates were not observed in
cells expressing GFP alone or GFP-TDP-4310-414-NLSm (Fig. 3B). More-
over, a small percentage of the cells with TDP-43-positive cytoplasmic
Fig. 2. ICV injection of AAV2/9-TDP-43 leads to expression of TDP-43 protein throughout mouse brain. Western blot (A) and densitometric quantiﬁcation analysis
(B) revealed that the levels of GFP-TDP-4310-414-NLSm protein at high dose were comparable to that of GFP-TDP-43NLSm at low dose. Expression of GFP-TDP-43NLSm and
GFP-TDP-4310-414-NLSm did not reduce the protein levels of endogenous mouse TDP-43 (B). (C) Quantitative RT-PCR (qRT-PCR) using speciﬁc primers against GFP or human
TDP-43 showed that the mRNA levels of GFP-TDP-4310-414-NLS were dramatically higher than that of GFP-TDP-43NLS. (D) qRT-PCR using speciﬁc primers for mouse TDP-43 or
mouse sortin1_17b showed that expression of GFP-TDP-43NLS or GFP-TDP-4310-414-NLS did not reduce mRNA levels of mouse TDP-43 nor induce aberrant splicing of mouse
sortilin 1. Data shown are the means7SEM of 3 mice per group. **Po0.01, ***Po0.001, ****Po0.0001 versus GFP-TDP-43NLSm (L), ####Po0.0001 versus
GFP-TDP-4310-414-NLSm (L), as assessed by one-way ANOVA with Tukey's post-hoc analysis.
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sent in brains of mice expressing GFP or GFP-TDP-4310-414-NLSm
(Fig. 3B). In addition, an astrocytic marker, glial ﬁbrillary acidic protein
(GFAP), was activated, but not a microglia marker, ionized calcium-
binding adaptor molecule 1 (Iba1), as indicated by mRNA and proteins
levels (Fig. 3D and E) in GFP-TDP-43NLSm mice, but not in mice ex-
pressing GFP-TDP-4310-414-NLSm or GFP alone.
Supplementary material related to this article can be found
online at http://dx.doi.org/10.1016/j.brainres.2016.04.069.3. Discussion
TDP-43 is the major protein component of ubiquitinated in-
clusions in FTLD-TDP and ALS (Arai et al., 2006; Neumann et al.,
2006). Under physiological conditions, TDP-43 predominantly lo-
calizes to the nucleus. However, a substantial loss of nuclear TDP-
43 is observed in neurons bearing aberrant cytoplasmic TDP-43
inclusions. Although it has remained unclear how aberrant TDP-43
protein causes neurodegeneration, mounting evidence points to a
Fig. 3. The extreme N-terminus regulates the aggregation of TDP-43 and neurotoxicity in vivo. (A) Mice expressing GFP alone or GFP-TDP-4310-414-NLSm splayed their hind
legs as normal escape response. In contrast, mice expressing GFP-TDP-43NLSm held their hind limbs close to their body, indicating neurological abnormalities.
(B) Immunoﬂuorescence staining with the GFP antibody revealed that some neurons of mice injected with GFP-TDP-43NLSm had small, dense cytoplasmic aggregates
(arrows), whereas the distribution pattern of GFP-TDP-4310-414-NLSm was diffuse. Of importance, caspase-3 activation was observed in the subset of neurons with TDP-43
aggregates in cerebral cortex of mice injected with GFP-TDP-43NLSm. The staining of active caspase-3 was not observed in neurons expressing GFP alone or
GFP-TDP-4310-414-NLSm. Scale bar represents 10 mm. (C) Double immunoﬂuorescence staining with GFP and ubiquitin antibodies in cerebral cortex of GFP-TDP-43NLSm mice
revealed that the TDP-43 cytoplasmic inclusions were ubiquitin-positive. The ubiquitin-positive TDP-43 inclusions were not observed in brains of GFP or
GFP-TDP-4310-414-NLSm mice. Scale bar represents 10 mm. (D) Quantitative PCR (qPCR) analysis of the relative mRNA levels of the astrocyte marker, GFAP, but not microglia
marker, Iba1, were signiﬁcantly increased in brains of GFP-TDP-43NLSm mice compared to GFP or GFP-TDP-4310-414-NLSm mice controls. (E) Cerebral cortex and hippocampal
sections stained with anti-GFAP antibody showed the activation of astrogliosis in mice expressing GFP-TDP-43NLSm but not GFP alone or GFP-TDP-4310-414-NLSm mice. Scale bar
represents 100 mm. Data shown are the means7SEM of 3 mice per group. *Po0.05, as assessed by one-way ANOVA with Tukey's post-hoc analysis.
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plasmic TDP-43 aggregates contributing to disease pathogenesis
(Lee et al., 2012). Recently, we and others demonstrated that ex-
pression of full length TDP-43 containing NLS mutations resulted
in cytoplasmic TDP-43 accumulation and aggregation in vitro and
in vivo (Barmada et al., 2010; Dayton et al., 2013; Elden et al., 2010;
Igaz et al., 2011; Walker et al., 2015; Winton et al., 2008; Zhang
et al., 2013). Moreover, the cytoplasmic accumulation and ag-
gregation of TDP-43 induced cellular toxicity in primary neurons
(Barmada et al., 2010; Zhang et al., 2013), and neurodegeneration
in rat and mouse models (Dayton et al., 2013; Igaz et al., 2011;
Walker et al., 2015). Of particular importance, we provided evi-
dence that showed deletion of the ﬁrst 10 N-terminal amino acids
(TDP-4310-414-NLSm) prevented TDP-43 aggregation and rescued
neurite outgrowth in primary neurons (Zhang et al., 2013). In the
present study, we further conﬁrmed that the GFP-TDP-43NLSm has
a much stronger effect than GFP-TDP-4310-414-NLSm to induce ac-
tivation of caspase-3 in mouse primary neuronal cultures, in-
dicating that this region is critical for TDP-43-mediated
neurodegeneration.
Next, we took advantage of the AAV2/9, which efﬁciently
mediates expression of transgenes in neuronal cells whenadministered to murine neonates through ICV injections (Chak-
rabarty et al., 2013), to express GFP-TDP-43NLSm or
GFP-TDP-4310-414-NLSm in mouse brain. Consistent with previous
ﬁndings (Dayton et al., 2013; Igaz et al., 2011; Walker et al., 2015),
we observed that mice expressing TDP-43NLSm developed beha-
vioral abnormalities, ubiquitin-positive TDP-43 aggregates for-
mation, and astrogliosis. In contrast, while acute cytoplasmic ac-
cumulation GFP-TDP-4310-414-NLSm in primary neurons causes a
mild toxicity possible through induction of cellular stress, chronic
expression of TDP-4310-414-NLSm in mouse brain did not lead to the
pathological abnormalities nor cause the behavioral deﬁcits. Of
relevance, most TDP-43NLSm detected in neurons was diffusely
accumulated in the cytosol and only a small portion had formed
aggregates. Considering the proportion of the neurons with TDP-
43 aggregates and activated caspase-3 was relatively low, cell
death associated with TDP-43 aggregates may only be partially
responsible for the observed neuropathological phenotypes in
TDP-43NLSm mice. Under normal conditions TDP-43 mainly resides
in the nucleus and participates in RNA metabolism, pre-mRNA
splicing, and transcription; although small amounts of cytoplasmic
TDP-43 also play a critical role in microRNA biogenesis (Buratti
et al., 2010; Kawahara and Mieda-Sato, 2012) and mRNA transport,
H. Sasaguri et al. / Brain Research 1647 (2016) 57–6462as well as protein translation (Colombrita et al., 2012; Liu-Yesu-
cevitz et al., 2014; Wang et al., 2008). Therefore, excessive accu-
mulation of diffuse full length TDP-43 in the cytosol may result in
dysfunctional RNA processing as reported previously (Igaz et al.,
2011), which may contribute to the observed neuropathological
phenotypes of TDP-43NLSm mice. In contrast, our previous study
has reported that deletion of the ﬁrst 10 amino acids led to loss of
TDP-43 biological activity (Zhang et al., 2013), thus the cyto-
plasmic accumulation of TDP-4310-414-NLSm may not be able per-
turb the mRNA metabolism and cause toxicity. Although several
studies have reported that reduction of mouse TDP-43 in trans-
genic mice expressing TDP-43NLSm contributes to neurodegenera-
tion (Igaz et al., 2011; Walker et al., 2015), we did not observed this
decrease of endogenous mouse TDP-43 protein in our TDP-43NLSm
mice, excluding this possibility. Lastly, we have reported that the
accumulation of nuclear TDP-43 is required to reach a certain
threshold to affect mouse endogenous TDP-43 levels (Xu et al.,
2010); the expression level of TDP-43NLSm in our mouse model
may not reach the threshold to reduce mouse TDP-43.4. Conclusions
Our results indicate that the extreme N-terminus of TDP-43
plays critical roles in regulating TDP-43 protein aggregation and
toxicity in vivo. As such, targeting TDP-43's extreme N-terminus to
inhibit its activity might be a potential therapeutic strategy to treat
ALS and FTD-TDP.5. Experimental procedures
5.1. Generation of various AAV2/1- and AAV2/9-TDP-43 vectors
GFP-tagged full-length human TDP-43NLSm and
TDP-4310-414-NLSm plasmids were generated as described previously
(Zhang et al., 2013). AAV2/1 and 2/AAV9-TDP-43 were prepared by
standard methods (Zhang et al., 2013). Brieﬂy, AAV vectors ex-
pressing GFP, GFP-TDP-43NLSm and GFP-TDP-4310-414-NLSm were
transfected with helper plasmids in HEK293 cells. Forty-eight hours
after transfection, the cells were harvested and lysed in the pre-
sence of 0.5% sodium deoxycholate and 50 U/ml Benzonase (Sigma)
by freeze thawing, and the virus was isolated using a discontinuous
iodixanol gradient centrifugation. The genomic titer of each virus
was determined by qRT-PCR, and the titer of the virus of GFP,
GFP-TDP-43NLSm, or GFP-TDP-4310-414-NLSm was 1.0–3.01013 viral
genomes per ml. When performed intracerebroventricular injec-
tions, the viruses were diluted with sterile phosphate-buffered
saline (PBS) and adjusted to the titer indicated in the text.
5.2. Mouse primary neuronal culture and virus treatment
Primary cortical neuronal cultures were prepared according to
protocol as we previously described (Zhang et al., 2013). In brief,
neurons that were isolated from the cortex from embryonic day 18
(E18) C57BL/6J pups were seeded at a density of 1105 cells/cov-
erslip in 24-well plates or 8105 cells/well in 6-well plates. At day in
vitro 4, neurons were transduced to express GFP, GFP-TDP-43NLSm, or
GFP-TDP-4310-414-NLSm. For 24-well plate, 4109 genome AAV2/1
virus of GFP, GFP-TDP-43NLSm or GFP-TDP-4310-414-NLSm was added to
the cell medium. For 6-well plate, since we observed that more virus
of GFP-TDP-4310-414-NLSm have to be used to get comparable protein
expression as GFPTDP-43NLSm, 11010 of particles of AAV2/1-GFP,
GFP-TDP-43NLSm were used and 1.51010 particles were used for
GFP-TDP-4310-414-NLSm. Five days after addition of AAV2/1 viral par-
ticles to the media, the cells grown in 24-well plate were ﬁxed with4% paraformaldehyde (PFA) and immunostained with a mouse
monoclonal anti-MAP2 antibody (Sigma, 1:1000) for immuno-
ﬂuorescence study. The cell pellets collected from a 6-well plate were
lysed using buffer (50 mM Tris–HCl, pH 7.4, 300 mM NaCl, 1% Triton
X-100, 5 mM EDTA, 2% SDS, PMSF, and protease and phosphatase
inhibitors). Lysates were sonicated and centrifuged at 16,000g for
20 min. Supernatants were saved and the protein concentration was
determined by BCA assay. Samples were then analyzed by Western
blot.
5.3. Intracerebroventricular injections of various AAV2/9-TDP-43
Intracerebroventricular (ICV) injections of AAV2/9 were per-
formed as previously described with minor modiﬁcations (Chak-
rabarty et al., 2013; Kim et al., 2013). Brieﬂy, a 32-gauge Hamilton
needle attached to a 10 ml Hamilton syringe is inserted at ap-
proximately two-ﬁfth of the distance between the lambda and eye
of P0 C57BL/6 J pups after they underwent cryoanesthesia on ice
for 3 min. The needle was inserted perpendicular to the surface of
the head and held at a depth of approximately 2 mm. Two ml of
AAV2/9 solution was manually injected to each cerebroventricle.
After injections, pups were placed on a heat pad until they com-
pletely recovered from anesthesia and put back to the cages. Motor
phenotype was assessed by clasping phenotype of hind limbs
while holding the tails. All procedures in this study were per-
formed in accordance with the National Institutes of Health Guide
for Care and Use of Experimental Animals and approved by the
Mayo Clinic Institutional Animal Care and Use Committee (Proto-
col number A37811). Of note, both high and low dose of
GFP-TDP-4310-414-NLSm viral particles were used for ICV injection
for the reason mentioned above.
5.4. Protein and RNA extraction from mouse brains
To extract both protein and RNA from the same brain sample,
brains were ﬁrst homogenized in ice-cold Tris-EDTA (10 mM Tris–
HCl, 0.1 mM EDTA, pH 8.0) buffer with 2X PMSF, protease and
phosphatase inhibitors, and RNase inhibitors (Ambion, AM2694)
by sonication. After all the visible chunks were broken, 2X lysis
buffer was added to one volume of the homogenates, and further
sonication was performed to extract proteins. To extract RNA,
3 volumes of TRIzol-LS (Invitrogen) were added to 1 volume of the
homogenates, and RNA was puriﬁed according to manufacturer's
instruction.
5.5. Western blotting
The samples from mouse primary neurons or mouse brains
were subjected to SDS-PAGE. After transfer, membranes were in-
cubated with rabbit polyclonal TDP-43 antibody (1:2000, Pro-
teintech), rabbit polyclonal GFP antibody (1:1000, Invitrogen),
rabbit polyclonal cleaved-caspase-3 antibody (1:1000, Cell Sig-
naling Technology) or mouse monoclonal α-tubulin antibody
(1:10000, Sigma-Aldrich). After incubating with an appropriate
secondary antibody, immunoreactivity was visualized by ECL, and
signals were recorded by FUJI ﬁlm imager.
5.6. Quantitative real-time PCR (qRT-PCR)
A total of 2 μg of RNA were used to synthesize cDNA using the
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems).
The qRT-PCR was performed using an HT7900 analyzer (Applied
Biosystems). Each 5 ml reaction contained: 2 ml of cDNA diluted 1:10,
0.5 ml primer mix (1 mM for each primer), and 2.5 ml SYBR green
(Invitrogen). The qRT-PCR program was as follows: 50 °C 2 min,
95 °C 2 min, 40 cycles of 95 °C 15 s and 60 °C 1 min. For dissociation
H. Sasaguri et al. / Brain Research 1647 (2016) 57–64 63curves, a dissociation stage of 95 °C 15 s, 60 °C 15 s was added at the
end of the program. Tardbp and GFP mRNA values were normalized
to Gapdh values, an endogenous transcript control. The data was
analyzed by using Software RQ Manager 1.2 (Applied Biosystems).
The primers used were: Gapdh: 5′-CATGGCCTTCCGTGTTCCTA-3′ and
5′-CCTGCTTCACCACCTTCTTGAT-3′; Tardbp: 5′-GGGGCAATCTGGTA-
TATGTTG-3′ and 5′-TGGACTGCTCTTTTCACTTTCA-3′; GFP: 5′-
GAAGCGCGATCACATGGT-3′ and 5′-CCATGCCGAGAGTGATCC-3′;
mSort1_17b: 5′-AAATCCCAGGAGACAAATGC-3′ and 5′-GAGCTG-
GATTCTGGGACAAG-3′; GFAP: 5′-GGAGAGGGACAACTTTGCAC-3′ and
5′-AGCCTCAGGTTGGTTTCATC-3′; Iba1: 5′-GGATTTGCAGGGAG-
GAAAAG-3′ and 5′-TGGGATCATCGAGGAATTG-3′.
5.7. Immunohistochemistry and immunoﬂuorescence
Tissues were embedded in parafﬁn, sectioned (5 mm thick) and
mounted on glass slides. Sections were deparafﬁnized in xylene
and rehydrated in a graded series of alcohol, followed by dH2O.
Antigen retrieval was performed in a dH2O steam bath for 30 min.
Tissues were immunostained with human-speciﬁc TDP-43
(1:6000, Novus Biologicals), glial ﬁbrillary acidic protein (GFAP)
(1:2500, Biogenex) and ionized calcium-binding adaptor molecule
1 (Iba-1) (1:2000, Wako Chemicals) antibodies, using the DAKO
Autostainer (Dako Auto Machine Corporation) and the DAKO En-
Visionþ HRP system. DAKO Liquid DAB Substrate–Chromogen
system was the chromogen. After immunostaining, sections were
brieﬂy counterstained with hematoxylin to visualize cell nuclei
and coverslipped. Parafﬁn-embedded sections were also stained
with hematoxylin and eosin. To examine the colocalization of TDP-
43 inclusions and active caspase-3, deparafﬁnized brain sections
were blocked with blocking solution (Dako), and incubated with
mouse monoclonal GFP antibody (1:1000, Invitrogen) and rabbit
polyclonal cleaved-caspase 3 antibodies (1:250, Cell Signaling
Technology). To determine whether TDP-43 inclusions are ubi-
quitin-positive, the sections were incubated with a rabbit poly-
clonal anti-GFP antibody (1:1000, Life Technologies) and a mouse
monoclonal anti-ubiquitin antibody (1:250, EMD Millipore). Fol-
lowing incubation with secondary antibody, the sections were
mounted with Hoechst 33258 (1 mg/ml, Invitrogen). Images were
obtained on a Zeiss LSM 510 META confocal microscope.
5.8. Statistics
One-way ANOVA with Tukey's posthoc analysis were used to
compare measures among 3 groups. Two-tailed student’s t-test
was used to compare measures among 2 groups. For data pre-
sentation, normalized values were averaged and presented as
mean7standard error of mean (SEM). Values of Po0.05 were
considered statistically signiﬁcant.Conﬂict of interest
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